Use of electrochemotherapy in a voluminous chest wall recurrence of triple-negative breast cancer: case report

Radica, Margherita Koleva; Fabbri, Nicolò; Santandrea, Giorgia; Bonazza, S; Stefanelli, Antonio; Carcoforo, Paolo

doi:10.21037/acr-20-54

Cited by 3 publications

(1 citation statement)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…If selinexor was included in our drug repository, it would probably be identified instead of LMB. For pathway-specific drugs, BC-related clinical trials using vincristine and bleomycin can be found, but bleomycin is usually applied to evaluate the effects of electrochemotherapy ( Radica et al, 2020 ).…”

Section: Resultsmentioning

confidence: 99%

XMR: an explainable multimodal neural network for drug response prediction

et al. 2023

View full text Add to dashboard Cite

Introduction: Existing large-scale preclinical cancer drug response databases provide us with a great opportunity to identify and predict potentially effective drugs to combat cancers. Deep learning models built on these databases have been developed and applied to tackle the cancer drug-response prediction task. Their prediction has been demonstrated to significantly outperform traditional machine learning methods. However, due to the “black box” characteristic, biologically faithful explanations are hardly derived from these deep learning models. Interpretable deep learning models that rely on visible neural networks (VNNs) have been proposed to provide biological justification for the predicted outcomes. However, their performance does not meet the expectation to be applied in clinical practice.Methods: In this paper, we develop an XMR model, an eXplainable Multimodal neural network for drug Response prediction. XMR is a new compact multimodal neural network consisting of two sub-networks: a visible neural network for learning genomic features and a graph neural network (GNN) for learning drugs’ structural features. Both sub-networks are integrated into a multimodal fusion layer to model the drug response for the given gene mutations and the drug’s molecular structures. Furthermore, a pruning approach is applied to provide better interpretations of the XMR model. We use five pathway hierarchies (cell cycle, DNA repair, diseases, signal transduction, and metabolism), which are obtained from the Reactome Pathway Database, as the architecture of VNN for our XMR model to predict drug responses of triple negative breast cancer.Results: We find that our model outperforms other state-of-the-art interpretable deep learning models in terms of predictive performance. In addition, our model can provide biological insights into explaining drug responses for triple-negative breast cancer.Discussion: Overall, combining both VNN and GNN in a multimodal fusion layer, XMR captures key genomic and molecular features and offers reasonable interpretability in biology, thereby better predicting drug responses in cancer patients. Our model would also benefit personalized cancer therapy in the future.

show abstract

Section: Resultsmentioning

confidence: 99%